Psychopharmacology of Fear-Potentiated Startle in Humans
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00044096|
Recruitment Status : Completed
First Posted : August 19, 2002
Last Update Posted : July 5, 2018
The purpose of this study is to understand the effects of the drug alprazolam (Xanax ) on anxiety.
To understand the effect of anxiety-relieving drugs on fear and anxiety, researchers often have participants anticipate unpleasant stimuli. Anticipating unpleasant stimuli increases or potentiates a simple reflex called the startle reflex. The so-called fear-potentiated startle reflex (FPS) effect may be blocked or reduced by anxiety-relieving drugs. Evidence suggests that the FPS can be mediated by two mechanisms that regulate the phasic- and sustained enhancement of startle. This study will elicit phasic and sustained FPS in participants by having them anticipate moderately painful stimuli that are administered predictably and unpredictably. The main goal of this study is to assess the affect of alprazolam on the phasic and sustained enhancement of startle.
This study comprises two pilot experiments and a main study. Participants in the study will be screened with a psychiatric history, physical examination, electrocardiogram (EKG), and blood and urine tests. Participants will four testing sessions separated by 5 to 10 days. At each session, participants will be given one of two doses of alprazolam, diphenhydramine, or placebo (an inactive pill). Questionnaires and other tests will be performed.
|Condition or disease|
Recent breakthroughs in biomedical research have not improved the ability to identify successful pharmacological treatments derived from novel candidate compounds. This is partly due to the inability of the existing scientific approach to translate candidate anxiolytics identified through the drug discovery process into efficient psychopharmacological treatment of patients. A new drug development approach urgently needs to be implemented to improve predictability and efficiency in translating the basic science explosion into validated drug targets. A key approach to improve the selection of candidate anxiolytics for clinical trials is to fill the gap between animal models and clinical studies in patients by implementing tests in healthy humans with a predictive validity of subsequent clinical efficacy. As a step towards this goal, we developed integrative experimental models of fear and anxiety in non-clinical subjects. We now use these models to identify the anxiolytic and anxiogenic properties of various compounds. The current specific objectives are to 1) further test the psychopharmacological validity of the model using recognized anxiolytics (the SSRI citalopram), 2) test the properties of compounds that are hypothesized to be anxiolytic or anxiogenic (e.g., oxytocin, arginine vasopressin, hydrocortisone) and 3) examine the time course of the anxiolytic effect of the benzodiazepine alprazolam on FPS.
Medically and psychiatrically healthy males and females ages 18 to 45.
The study examines fear and anxiety elicited by unpleasant electric shock delivered predictably and unpredictably, respectively. The following drugs will be tested:
1) Citalopram, 2) oxytocin and arginine vasopressin, 3) hydrocortisone, 4) alprazolam.
The primary outcome measure is the startle reflex. Secondary measures include the skin conductance response, the heart rate, and subjective measures of anxiety.
|Study Type :||Observational|
|Actual Enrollment :||225 participants|
|Official Title:||Psychopharmacology of Fear-Potentiated Startle in Humans|
|Study Start Date :||August 15, 2002|
|Study Completion Date :||September 17, 2013|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00044096
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Christian Grillon, Ph.D.||National Institute of Mental Health (NIMH)|